asbestos-related cancer mesothelioma, Alimta will be given to NHS patients

asbestos-related cancer mesothelioma, Alimta will be given to NHS patients

Jan 24 2008 by Audrey Barton, The Journal

NORTH-EAST campaigners have won their three-year battle to get a
life-prolonging lung cancer drug funded on the NHS.

Alimta, which is the only treatment for asbestos-related cancer
mesothelioma, will be given to NHS patients with advanced stages of the
disease who cannot have surgery.

The National Institute for Health and Clinical Excellence (NICE) yesterday
issued guidance following a two-and-a-half year approval process, which
included two appeals.

The guidance means that primary care trusts (PCTs) will be able to fund
the drug for all NHS patients with mesothelioma for whom the treatment is
suitable.

The North-East has one of the highest concentrations of the disease which
has its roots in heavy industry such as shipbuilding.

Chris Knighton, of Wallsend, North Tyneside, lost her husband Mick to
mesothelioma, prompting her to raise more than £330,000 for research.

The founder of the Mick Knighton Mesothelioma Research Fund said: “I am
absolutely delighted as really today is a victory for us as we have been
fighting for this for three years.

“I think that hopefully in the future making the drug accessible to
patients who have had surgery is something that could be possibly looked
at to make it accessible for more patients. My concern is that now PCTs
make the drug available for mesothelioma patients as they don’t have the
benefit of time.”

Arthur Tiffin, 53, of North Walbottle, Newcastle, who died from
mesothelioma last summer, led the campaign to make Alimta available for
patients in the region which was successful in 2005. NICE initially ruled
against the use of Alimta across the NHS but made a U-turn last year and
issued guidance recommending the life prolonging drug.

But two appeals were lodged in September, the first for the drug to be
extended for people who had surgery, and the second stating that it did
not fall within the special criteria for funding drugs over a £30,000
threshold have been dismissed on all counts. Yesterday’s recommendation
was delayed by several months subject to an appeal hearing but marks the
end of a long running battle for the drug to be funded on the NHS.

Blaydon MP Dave Anderson, a patron of the Mick Knighton Mesothelioma
Research Fund charity, said: “The Government now needs to ensure that
there is a level playing field across the whole of the UK for workers
stricken by this disease.

“It is only right that treatment is available according to need and not
cost.

“However, the delay getting this decision has added to the mental and
physical anguish for sufferers and has sadly come too late for some.”

He is calling on PCTs to immediately fund the treatment and not wait until
the end of the three month implementation period.

--------------------------------------------------------------------------------------------------

From a lung cancer forum.
J